Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant

Vaccine

Volumn 19, Issue 11-12, 2001, Pages 1460-1466

  Isaka, Masanori ^a   Yasuda, Yoko ^a   Mizokami, Masashi ^a   Kozuka, Satoshi ^a   Taniguchi, Tooru ^a   Matano, Keiko ^a   Maeyama, Jun ichi ^b   Mizuno, Kyosuke ^c   Morokuma, Kazunori ^c   Ohkuma, Kunio ^c   Goto, Norihisa ^b   Tochikubo, Kunio ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c Kaketsuken   (Japan)

Author keywords

Hepatitis B surface antigen; Intranasal immunization; Recombinant cholera toxin B subunit (rCTB)

Indexed keywords

CHOLERA TOXIN B SUBUNIT; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN 2B ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; LUNG; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NOSE CAVITY; PRIORITY JOURNAL; SALIVA; SMALL INTESTINE; TH1 CELL; TH2 CELL; VAGINA; VIRUS TITRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CHOLERA TOXIN; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; VACCINES, SYNTHETIC;

EID: 0035825081     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00348-0     Document Type: Article

References (40)

1. Global status of hepatitis B immunisation
2. Global control of hepatitis B through vaccination: The role of hepatitis B vaccine in the expanded programme on immunization
3. Recommendations of the Immunization Practises Advisory Committee. Update on hepatitis B prevention
4. Advantages of aluminium hydroxide adsorbed combined diphtheria, tetanus, and pertussis vaccines for the immunization of infants
5. Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts
6. Studies on antibody production. III. The alum granuloma
7. Aluminium hydroxide granuloma
8. Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid
9. Local histopathological reactions to aluminum-adsorbed tetanus toxoid
10. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties
11. Aluminium phosphate but not calcium phosphate stimulates the specific IgE response in guinea pigs to tetanus toxoid
12. Adjuvant effects of amorphous silica and of aluminium hydroxide on IgE and IgG1 antibody production in different inbred mouse strains
13. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid
14. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
15. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
16. CpG DNA as mucosal adjuvant
17. CpG DNA induces stronger immune responses with less toxicity than other adjuvants
18. Cholera toxin as a mucosal adjuvant
19. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens
20. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity
21. Humoral and cellular immune responses in the murine respiratory tract following oral immunization with cholera toxin or Escherichia coli heat-labile enterotoxin
22. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin
23. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: Role of the A subunit
24. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated infuenza virus vaccine
25. Genetically derived toxoids for use as vaccines and adjuvants
26. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit
27. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant
28. Efficient extracellular production of recombinant Escherichia coli heat-labile enterotoxin B subunit by using the expression/secretion system of Bacillus brevis and its mucosal immunoadjuvanticity
29. Affinity purification of recombinant cholera toxin B subunit oligomer expressed in Bacillus brevis for potential human use as a mucosal adjuvant
30. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant
31. Hepatitis B vaccination
32. Hepatitis B vaccine and central nervous system demyelinating diseases
33. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens
34. Oral administration of cholera toxin-sendai virus conjugates potentiates gut and respiratory immunity against sendai virus
35. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues
36. A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization
37. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant
38. Mucosal and systemic antibody responses after peroral or intranasal immunization: Effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant
39. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin